Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α-2a (40 kDa) plus ribavirin: Impact on health-related quality of life

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 2, 2006, Pages 406-412

  Arora, Sanjeev ^a   O'Brien, Christopher ^b   Zeuzem, Stefan ^g   Shiffman, Mitchell L ^c   Diago, Moises ^h   Tran, Albert ⁱ   Pockros, Paul J ^d   Reindollar, Robert W ^e   Gane, Edward ^j   Patel, Kavita ^f   Wintfeld, Neil ^f   Green, Jesse ^f  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d SCRIPPS CLINIC   (United States)

^e Carolinas Center for Liver Disease   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g SAARLAND UNIVERSITY   (Germany)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j MIDDLEMORE HOSPITAL   (New Zealand)

more..

Author keywords

Combination therapy; Health related quality of life; Peginterferon 2a; Persistently normal ALT levels; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; ERADICATION THERAPY; FATIQUE SEVERITY SCALE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSTRUMENT; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; PHYSICAL COMPONENT SCORE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDITY; VIROLOGY; VIRUS INHIBITION;

EID: 33645241106     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04059.x     Document Type: Article

References (38)

1. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. June 10-12, 2002 Hepatology 2002 36 S3 20
2. Strader DB Wright T Thomas DL Seeff LB. Diagnosis, management, and treatment of hepatitis C Hepatology 2004 39 1147 71
3. Manns MP McHutchison JG Gordon S et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001 358 958 65
4. Fried MW Shiffman ML Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection NEnglJMed 2002 347 975 82
5. Hadziyannis SJ Sette HJ Morgan TR et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose AnnInternMed 2004 140 346 55
6. Marcellin P Boyer N Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy AnnInternMed 1997 127 875 81
7. Ware JE Jr. Bayliss MS Mannocchia M Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group Hepatology 1999 30 550 5
8. McHutchison JG Ware JE Jr. Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity JHepatol 2001 34 140 7
9. Bernstein D Kleinman L Barker CM Revicki DA Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients Hepatology 2002 35 704 8
10. Rasenack J Zeuzem S Feinman SV et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C Pharmacoeconomics 2003 21 341 9
11. Hassanein T Cooksley G Sulkowski M et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C JHepatol 2004 40 675 81
12. Poynard T Ratziu V Charlotte F Goodman Z McHutchison J Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C JHepatol 2001 34 730 9
13. Poynard T McHutchison J Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 2002 122 1303 13
14. Camma C Di Bona D Schepis F et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data Hepatology 2004 39 333 42
15. Coverdale SA Khan MH Byth K et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study AmJGastroenterol 2004 99 636 44
16. Yoshida H Arakawa Y Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 2002 123 483 91
17. Camma C Di Marco V Lo Iacono O et al. Long-term course of interferon-treated chronic hepatitis C JHepatol 1998 28 531 7
18. Imazeki F Yokosuka O Fukai K Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study Hepatology 2003 38 493 502
19. Alberti A Noventa F Benvegnu L Boccato S Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection AnnInternMed 2002 137 961 4
20. Ahmed A Keeffe EB. Chronic hepatitis C with normal aminotransferase levels Gastroenterology 2004 126 1409 15
21. Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why Hepatology 1999 29 277 9
22. Foster GR Goldin RD Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis Hepatology 1998 27 209 12
23. Bonkovsky HL Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group Hepatology 1999 29 264 70
24. a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 2004 127 1724 32
25. Ware JE Jr. Snow KK Kosinski M Gandek B. SF-36 Health Survey: Manual and Interpretation Guide Boston, MA The Health Institute, New England Medical Center 1993
26. Foster GR. Hepatitis C virus infection: quality of life and side effects of treatment JHepatol 1999 31 Suppl. 1 250 4
27. Kleinman L Zodet MW Hakim Z et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C QualLife Res 2000 9 499 508
28. Hassoun Z Willems B Deslauriers J Nguyen BN Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale DigDisSci 2002 47 2674 81
29. Amante Grey P Wild D Hakim Z Green J Krupp L. Cross cultural adaptation of a fatigue severity scale. Presented at the Ninth International Congress on Infectious Diseases. Buenos Aires, Argentina April 10-13, 2000.
30. Bozdogan H. Model selection and Akaike's Information Criterion (AIC): the general therory and its analytical extensions Psychometrika 1987 52 345 70
31. Shiffman ML Diago M Tran A et al. Natural history of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels: data from the multinational PEGASYS study (NR 16071) Hepatology 2003 38 4 Suppl. 1 434 5A
32. Neary MP Cort S Bayliss MS Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients SeminLiver Dis 1999 19 Suppl. 1 77 85
33. Bayliss MS Gandek B Bungay KM Sugano D Hsu MA Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C QualLife Res 1998 7 39 55
34. Davis GL Balart LA Schiff ER et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile ClinTher 1994 16 334 43 ; discussion 271-2.
35. Hunt CM Dominitz JA Bute BP Waters B Blasi U Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life DigDisSci 1997 42 2482 6
36. Hussain KB Fontana RJ Moyer CA Su GL Sneed-Pee N Lok AS. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C AmJGastroenterol 2001 96 2737 44
37. Rodger AJ Jolley D Thompson SC Lanigan A Crofts N. The impact of diagnosis of hepatitis C virus on quality of life Hepatology 1999 30 1299 301
38. von Wagner M Lee J-H Friedl R Kronenberger B Sarrazin C Zeuzem S. Impaired quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels Hepatology 2003 38 454A